Related Experiment Video
Updated: Jan 14, 2026

Modeling The Lifecycle Of Ebola Virus Under Biosafety Level 2 Conditions With Virus-like Particles Containing Tetracistronic Minigenomes
Published on: September 27, 2014
Infection-sensing minigenome as a novel therapeutic approach against Ebola virus
Lin Wang1, Brady N Zell2, Brian J Parrett2
1Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
Abstract:
We describe here a molecular therapy that uses the virus's own proteins to combat itself. In this approach, infection-sensing RNAs encoding therapeutic genes are flanked by viral promoters and packaging signals in negative-sense orientation. These therapeutic minigenome RNAs do not express the transgene and remain silent in the absence of a viral infection. In contrast, if the cell is infected, the virus acts as a helper virus, providing viral proteins in trans to transcribe, replicate, and package the therapeutic minigenomes. Proof of concept for this therapeutic approach is demonstrated here using Ebola virus (EBOV) minigenomes expressing two antiviral transgenes: a short-hairpin (sh) RNA targeting the EBOV viral protein VP24 and an open-reading frame expressing a host peptide from the retinoblastoma-binding protein 6 (RBBP6). By using an EBOV tetracistronic-minigenome as a virus life cycle modeling system, we show here that both therapeutic minigenomes suppressed viral RNA replication and viral protein production, and a more than 50% reduction in the reporter signal was observed when cells were challenged with EBOV transcription/replication-competent virus-like particles. These findings highlight the therapeutic potential of infection-sensing minigenome to combat EBOV and perhaps other viral pathogens.

